ModifiedArizona Complete HealthPolicy CP.MP.150

Phototherapy for Neonatal Hyperbilirubinemia

Medical necessity criteria and coverage stance for home and inpatient phototherapy and exchange transfusion for neonatal hyperbilirubinemia, directed to clinicians and payers managing newborns ≥38 weeks gestation and related services.

Policy Summary

PayerArizona Complete Health

PolicyPhototherapy for Neonatal Hyperbilirubinemia

Policy CodePolicy CP.MP.150

Change TypeWording clarifications and material edits (G6PD wording updateclarified inpatient extenuating circumstances)

Effective Date

Next Review Date

Key ActionDocument infant eligibility and daily TSB measurements, ensuring infant is ≥38 weeks gestation and a primary care provider is available for 12–24 hour follow-up.

SourceLink

POLICY UPDATE CHANGES

Updated Criteria I.J.1. wording from glucose-6-phosphate dehydrogenase (G6PD) to G6PD deficiency.

Rearranged verbiage regarding infants ≥ 38 weeks gestation in Criteria I. and I.A., and removed 'Term' verbiage in Criteria I.B.

Clarified that extenuating circumstances for inpatient phototherapy can include lack of expected compliance with therapy at home.

17Explicit listed infant risk-factor/exclusion items for home phototherapy

≥38wGestational age threshold for home phototherapy eligibility

≤11–17Acceptable TSB range by age for home phototherapy

Daily

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Phototherapy and Exchange Transfusion

Home Phototherapy Eligibility

Covered when ALL of the following are met:

Home phototherapy criteria

Risk factor exclusions (none should be present): Isoimmune hemolytic disease (e.g., positive direct antiglobulin test), G6PD deficiency, or other hemolytic disease; hypoxic ischemia encephalopathy/asphyxia; temperature instability; sepsis; acidosis; albumin < 3.0 g/dL if measured; birth weight < 2500 g; significant cephalohematoma or bruising; weight loss ≥ 10%; elevated direct-reacting/conjugated bilirubin; jaundice appearing in first 24 hours of life; laboratory or clinical evidence of hypothyroidism; significant clinical instability in the previous 24 hours; clinical history of a parent or sibling requiring phototherapy or exchange transfusion; exclusive breastfeeding or chestfeeding with suboptimal intake; Down syndrome; macrosomic infant of a diabetic mother
None of these risk factors may be present for home phototherapy eligibility.

TSB age-based threshold: TSB is within the levels noted in Table 1 for infants without risk factors: 24–36 hours ≤11 mg/dL; 36–48 hours ≤14 mg/dL; 48–60 hours ≤15 mg/dL; 60–72 hours ≤16 mg/dL; >72 hours ≤17 mg/dL.

TSB must be within these age-based limits for home phototherapy.

Inpatient Phototherapy / Exchange Transfusion

Inpatient phototherapy or exchange transfusion is covered when:

Inpatient/exchange indications: Criteria for inpatient phototherapy or exchange transfusion per the most current nationally recognized decision support tools are met; OR TSB concentration is more than 1 mg/dL above the American Academy of Pediatrics (AAP) phototherapy treatment threshold per the bili risk tool; OR extenuating circumstances make home therapy unsafe or unlikely to be adhered to (for example, expected lack of ability to adhere to therapy at home).

Meeting any one of these conditions supports inpatient treatment or exchange transfusion.

ICD-10 diagnosis code lists previously included in this policy have been removed. The policy no longer lists specific ICD-10 codes for neonatal hyperbilirubinemia; coverage determinations should be made using the clinical criteria and requirements stated in this document rather than diagnosis code lists.

This clinical policy is a guide to medical necessity and coverage decisions and was developed by qualified clinicians based on available evidence and standards of practice. Coverage determinations remain subject to the member's plan documents and applicable state and federal laws. Where state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid provisions take precedence.

Home phototherapy is appropriate only when the infant meets all eligibility criteria listed in this policy. Home phototherapy is not appropriate when the infant does not satisfy the listed criteria (for example, gestational age < 38 weeks, clinical instability, listed risk factors present, no LED device available, inability to obtain daily TSB measurements, or lack of timely follow-up) or when the infant's Total Serum Bilirubin (TSB) is >1 mg/dL above the AAP phototherapy treatment threshold as identified in the AAP bili risk calculator; such situations warrant inpatient phototherapy or other escalation of care.

Coding and Thresholds

Referenced CodesHCPCS | CPT

E0202	Phototherapy (bilirubin) light with photometer.
S9098	Home visit, phototherapy services (e.g., Bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem

TSB age-based thresholds for home phototherapy

24–36 hoursTSB ≤ 11 mg/dL

36–48 hoursTSB ≤ 14 mg/dL

48–60 hoursTSB ≤ 15 mg/dL

60–72 hoursTSB ≤ 16 mg/dL

>72 hoursTSB ≤ 17 mg/dL

Provider Responsibilities, Prior Authorization, and Documentation

Denial Risk

Triggers for denial of home phototherapy

Inpatient phototherapy should be used (home phototherapy denied) when the infant does not meet the criteria for home phototherapy, including any of the risk factors or TSB thresholds listed in the policy. Specifically, home phototherapy is not appropriate and may be denied when: the infant is < 38 weeks gestation; age < 48 hours; feeding poorly or clinically unstable; lactation support has not been offered when breastfeeding/chestfeeding; no primary care provider is willing to manage home care with timely follow-up; prior phototherapy has already been given; an LED-based device cannot be made available in the home without delay; or the infant has any listed risk factors (e.g., isoimmune hemolytic disease, G6PD deficiency, HIE/asphyxia, temperature instability, sepsis, acidosis, albumin <3.0 g/dL, birth weight <2500 g, significant cephalohematoma or bruising, weight loss ≥10%, elevated direct/conjugated bilirubin, jaundice in first 24 hours, hypothyroidism, recent clinical instability, family history of severe neonatal jaundice or exchange transfusion, exclusive breastfeeding with suboptimal intake, Down syndrome, macrosomic infant of a diabetic mother). Home phototherapy will also be denied if the measured total serum bilirubin (TSB) exceeds the acceptable levels for home phototherapy (see Table 1) or is >1 mg/dL above the AAP phototherapy treatment threshold per the AAP risk calculator.

Infant < 38 weeks gestation
Infant < 48 hours old
Feeding poorly or clinically unstable
Lactation support not offered when breastfeeding/chestfeeding

Background and Scope

Neonatal hyperbilirubinemia is common. Rising total serum bilirubin (TSB) can lead to acute bilirubin-induced neurologic dysfunction (BIND) and, when severe, permanent injury (kernicterus). Phototherapy, preferably using LED devices in the blue-green spectrum (approximately 460–490 nm) with adequate irradiance, is the first-line treatment to reduce TSB. For otherwise-healthy infants who meet the policy's eligibility criteria, phototherapy may be delivered in the home setting with close follow-up and daily TSB monitoring to reduce the need for readmission; infants who do not meet criteria or who have TSB levels exceeding treatment thresholds should receive inpatient phototherapy or exchange transfusion per recognized decision support tools.

Definitions and Phototherapy Types

Conventional/intensive phototherapy

DefinitionPhototherapy delivered by a single light source in the blue-green spectrum (approximately 460–490 nm).

Preferred intensive phototherapyDelivered as intensive phototherapy achieving irradiance ≥30 µW/cm2 per nm measured at the infant's skin.

Delivery settingsConventional phototherapy may be delivered in the hospital or in the home setting.

BIND / kernicterus

DefinitionAcute bilirubin-induced neurologic dysfunction (BIND) that can progress to chronic, permanent neurologic injury termed kernicterus when unconjugated bilirubin crosses the blood-brain barrier.

Clinical significanceRising TSB can cause acute neurotoxicity; screening for hyperbilirubinemia should be conducted on all infants prior to discharge.